Aparicio I, Martínez A, Hernández G, Hardisson D, De Santiago J
Department of Obstetrics and Gynecology, University Hospital La Paz, Madrid, Spain.
Eur J Obstet Gynecol Reprod Biol. 2008 Apr;137(2):222-6. doi: 10.1016/j.ejogrb.2007.03.021. Epub 2007 May 3.
Pure squamous cell carcinoma (SCC) of the breast is a rare tumour and its clinical behaviour is not correctly known. The aim of the study is to evaluate the prevalence, epidemiological and clinical characteristics of the cases of SCC studied in our institution.
The breast department's database was searched for patients diagnosed with breast SCC between September 1979 and June 2006. Pathological features, outcome aspects and prognosis were studied. All specimens were reviewed by our pathologist who performed inmunohistochemistry for hormone receptors.
Eleven patients were identified (0.19%) between 5771 cases of breast cancer. Mean age was 64 (37-76) years and mean follow-up was 46 (6-216) months. Mean disease free survival (DFS) was 92 months (S.E.=33), with a 36% DFS rate at 5 years and the mean overall survival was 93 months (S.E.=34). Mean survival from the time recurrent disease was recognized was 9 (1-16) months. Tumours were hormone receptor negative.
SCC of the breast is aggressive and often treatment-refractory. The role of different new chemotherapy regimens need to be explored.
乳腺纯鳞状细胞癌（SCC）是一种罕见肿瘤，其临床行为尚不完全清楚。本研究旨在评估我院所研究的乳腺SCC病例的患病率、流行病学及临床特征。
检索乳腺科1979年9月至2006年6月期间诊断为乳腺SCC的患者数据库。对病理特征、转归情况及预后进行研究。所有标本均由我院病理学家复查，并进行激素受体免疫组化检测。
在5771例乳腺癌患者中确诊11例（0.19%）。平均年龄64岁（37 - 76岁），平均随访时间46个月（6 - 216个月）。平均无病生存期（DFS）为92个月（标准误=33），5年DFS率为36%，平均总生存期为93个月（标准误=34）。复发疾病确诊后的平均生存期为9个月（1 - 16个月）。肿瘤激素受体阴性。
乳腺SCC具有侵袭性，且常对治疗耐药。需要探索不同新化疗方案的作用。
